

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/072784 A1

(51) International Patent Classification⁷: **A61L 15/38**,
15/60

(21) International Application Number:
PCT/GB2005/000312

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04250508.1 30 January 2004 (30.01.2004) EP
0427444.5 15 December 2004 (15.12.2004) GB

(71) Applicant (*for all designated States except US*): **INSENSE LIMITED** [GB/GB]; Colworth Science Park, Sharnbrook, Bedford MK44 1LQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAVIS, Paul, James** [GB/GB]; The Hawthorns, Pavenham Road, Felmersham, Bedfordshire MK3 7EX (GB). **AUSTIN, Andrew, John** [GB/GB]; 85 Gypsy Lane, Irchester, Northants NN29 7DJ (GB). **JEZEK, Jan** [CZ/GB]; 5 Wwttnhall Road, Stanwick, Northants NN9 6TE (GB).

(74) Agent: **KEITH W NASH & CO**; 90-92 Regent Street, Cambridge CB2 1DP (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: WOUND DRESSINGS COMPRISING HYDRATED HYDROGELS AND ENZYMES

(57) Abstract: A skin dressing comprises a hydrated hydrogel material including a source of lactate ions and a supply of glucose, optionally also including a source of zinc ions and a source of iodide ions. The dressing has beneficial effects on skin.



WO 2005/072784 A1

WOUND DRESSINGS COMPRISING HYDRATED HYDROGELS AND ENZYMES

Field of the Invention

This invention relates to skin dressings for application to a part of a human or animal body for treatment of skin (for therapeutic or cosmetic purposes), and relates particularly (but not exclusively) to wound dressings for treatment of compromised skin, particularly skin lesions, i.e. any interruption in the surface of the skin, whether caused by injury or disease, including skin ulcers, burns, cuts, punctures, lacerations, blunt traumas, acne lesions, boils etc.

Background to the Invention

Skin and wound dressings are designed to undertake a number of important functions to aid the process of healing. Experts agree on most of the functions that an ideal dressing should provide, and these include:

- Donation of moisture to dry wounds
- Absorption of excess fluid from weeping wounds
- Maintenance of a moist environment around the wound bed
- Binding of water sufficiently well to prevent maceration (water-logging) of the normal tissue
- Aiding debridement (removal of dead tissue and scar material)
- Prevention of infection and provision of a barrier to escaping or invading microbes
- Killing infecting microbes
- Cushioning against further physical trauma
- Maintaining an optimum temperature through thermal insulation

- Allowing ingress of plentiful oxygen
- Soothing painful and inflamed open wound sites
- Flexibly adapting to the shape of the wound site
- Keeping its physical integrity so that fragmented dressing debris is not left in the wound
- Exerting no cytotoxic nor physically damaging effects on the healing cells.

In addition, the handling and physical design characteristics should make the dressing easy to use and comfortable to wear. For storage and distribution purposes, the dressing should be stable at ambient temperatures, and robust. Ideally it should be simple to manufacture, in order to allow its production and sale at a price that is affordable for widespread use.

These and other demands make the design of an ideal wound dressing almost impossible. To date, all wound dressings are a compromise, such that none offers all of the much desired characteristics in one product. For this reason, there are numerous different wound dressings on the market, and the typical nurse caring for patients with wounds needing professional care will select different dressings for different wounds and for wounds at different phases of the wound healing process. Manufacturers are constantly seeking new ways to make more effective wound dressings, which means that they are trying to make dressings that incorporate more of the characteristics and functions listed above. With the achievement of each new benefit, the cause of improved patient welfare is advanced, as the result of faster healing, reduction of pain and improvement in the quality of life. Medical care in general can benefit from such progress. Although these advanced, "active" dressings usually cost more, they can reduce the overall time during which a wound needs attention and reduce the amount of nursing time devoted to frequent changes of dressing. This drives down the huge cost borne by modern society in caring for wounds.

Our British Patent Application No. 0313217.2 filed on 9th June 2003 and International Application No. PCT/GB2004/002374 filed 4th June 2004 disclose a skin dressing comprising a first dressing component carrying oxidoreductase enzyme in dried condition;

and a second dressing component carrying a source of water, such that when the first and second dressing components are placed in fluid communication with each other, water migrates from the second component towards the first component and acts to hydrate enzyme carried by the first component, at least at the surface of the first component.

In one embodiment, the second dressing component comprises a hydrogel formulated to include the following reagents by weight:

20% sodium AMPS (2-acrylamido-2-methylpropanesulfonic acid, sodium salt (Lubrizol, code 2405))

0.2% poly ethylene glycol 400 diacrylate (UCB Chemicals)

0.01% photoinitiator (1-hydroxycyclohexyl phenyl ketone (Aldrich))

20% glucose (Fisher)

0.1% zinc lactate (Sigma)

0.05% potassium iodide (Fisher)

To 100% with DI-water.

It has now surprisingly been appreciated that such a hydrogel may to advantage be used on its own for skin treatment, not necessarily in combination with a first dressing component as disclosed in our earlier applications.

Summary of the Invention

In one aspect the present invention provides a skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose.

In a further aspect, the invention provides a skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose, excluding a hydrated hydrogel comprising the following reagents by weight: 20% sodium AMPS (2-acrylamido-2-methylpropanesulfonic acid, sodium salt (Lubrizol, code 2405)), 0.2% poly ethylene glycol 400 diacrylate (UCB Chemicals), 0.01% photoinitiator (1-hydroxycyclohexyl

phenyl ketone (Aldrich)), 20% glucose (Fisher), 0.1% zinc lactate (Sigma), 0.05% potassium iodide (Fisher) and to 100% with DI-water.

In another aspect, the invention provides a skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose, wherein the glucose is present in an amount of less than 20% by weight of the weight of the hydrated hydrogel material.

A hydrated hydrogel means one or more water-based or aqueous gels, in hydrated form.

A hydrated hydrogel can act to absorb water and other materials exuded from a wound site, enabling the dressing to perform a valuable and useful function by removing such materials from a wound site. The hydrated hydrogel also provides a source of moisture, that can act in use to maintain a wound site moist, aiding healing.

The hydrated hydrogel conveniently comprises hydrophilic polymer material. Suitable hydrophilic polymer materials include polyacrylates and methacrylates, e.g. as supplied by First Water Ltd in the form of proprietary hydrogels, including poly 2-acrylamido-2-methylpropane sulphonic acid (polyAMPS) or salts thereof (e.g. as described in WO 01/96422), polysaccharides e.g. polysaccharide gums particularly xanthan gum (e.g. available under the Trade Mark Keltrol), various sugars, polycarboxylic acids (e.g. available under the Trade Mark Gantrez AN-169 BF from ISP Europe), poly(methyl vinyl ether co-maleic anhydride) (e.g. available under the Trade Mark Gantrez AN 139, having a molecular weight in the range 20,000 to 40,000), polyvinyl pyrrolidone (e.g. in the form of commercially available grades known as PVP K-30 and PVP K-90), polyethylene oxide (e.g. available under the Trade Mark Polyox WSR-301), polyvinyl alcohol (e.g. available under the Trade Mark Elvanol), cross-linked polyacrylic polymer (e.g. available under the Trade Mark Carbopol EZ-1), celluloses and modified celluloses including hydroxypropyl cellulose (e.g. available under the Trade Mark Klucel EEF), sodium carboxymethyl cellulose (e.g. available under the Trade Mark Cellulose Gum 7LF) and hydroxyethyl cellulose (e.g. available under the Trade Mark Natrosol 250 LR).

Mixtures of hydrophilic polymer materials may be used in a gel.

In a hydrated hydrogel of hydrophilic polymer material, the hydrophilic polymer material is desirably present at a concentration of at least 1%, preferably at least 2%, more preferably at least 5%, yet more preferably at least 10%, or at least 20%, desirably at least 25% and even more desirably at least 30% by weight based on the total weight of the gel. Even higher amounts, up to about 40% by weight based on the total weight of the gel, may be used.

Good results have been obtained with use of a hydrated hydrogel of poly AMPS or salts thereof in an amount of about 30% by weight of the total weight of the gel.

By using a gel comprising a relatively high concentration (at least 2% by weight) of hydrophilic polymer material, the gel can function particularly effectively to take up water in use of the dressing, e.g. from serum exudates while in contact with a wound. Because the gel is an aqueous system, use of the dressing does not have the effect of inducing an overall dryness of the wound which would be undesirable. This is because water vapour pressure is maintained in the enclosed environment surrounding the skin in use of the dressing. The gel thus functions as an absorbent entity for the removal of moisture, e.g. wound exudate, that also provides a helpful background level of excess moisture.

The water-uptake capacity of a hydrated hydrogel, including a high concentration gel, enables the dressing to aid wound healing by removing substantial amounts of exudates, swelling-up as it does so. By using a carefully formulated, ready-hydrated gel, the wound is prevented from reaching a state of unhelpful dryness. Ready hydration also ensures the quick formation of an aqueous liquid interface between the dressing and the wound, thus preventing adhesion, which otherwise would interfere with easy lifting of the dressing when it has to be replaced. A good aqueous liquid interface between the wound and the dressing is also important in allowing any beneficial products carried in the gel to enter the wound through all of the available surface.

The hydrated hydrogel material is typically in the form of a solid layer, sheet or film of material that is typically cross-linked, and that may incorporate a mechanical reinforcing structure. The size and shape of the layer, sheet or film can be selected to suit the intended use of the dressing. Thicknesses in the range 0.01 to 1.0 mm, preferably 0.05 to 0.5 mm are particularly suitable.

Alternatively, the hydrated hydrogel may be in the form of an amorphous gel not having a fixed form or shape, that can be deformed and shaped in three dimensions, including being squeezed through a nozzle. Amorphous gels are typically not cross-linked or have low levels of cross-linking. A shear-thinning amorphous gel may be used. Such a gel is liquid when subjected to shear stress (e.g. when being poured or squeezed through a nozzle) but set when static. Thus the gel may be in the form of a pourable or squeezable component that may be dispensed, e.g. from a compressible tube or a syringe-like dispenser, comprising a piston and cylinder, typically with a nozzle of about 3 mm diameter. Such a gel may be applied in the form of a surface layer, or into a wound cavity as a fully conformable gel that fills the available space and contacts the wound surface.

A typical example of an amorphous gel formulation is: 15% w/w AMPS (sodium salt), 5% w/w glucose, 0.05% w/w potassium iodide, 0.1% zinc lactate, 0.19% polyethylene glycol diacrylate and 0.01% hydroxycyclohexyl phenyl ketone, with the volume made up to 100% with analytical grade DI water. The reagents are thoroughly mixed and dissolved, then polymerised for between 30-60 seconds, using a UV-A lamp delivering approximately 100 mW/cm², to form the required hydrogel. This may be contained in plastic syringes from which the amorphous gel may then be dispensed from a syringe to a target site, as a surface layer or to fill a cavity.

The source of lactate ions may be any compound capable of releasing lactate ions or lactate-containing ions in water. The lactate ion (derived from lactic acid) is optically active and so may exist in two enantiomeric forms, L- and D-, and as a mixture of both enantiomers, known as a racemate. Any enantiomeric form, or any mixture of enantiomeric forms, is suitable for use herein. Convenient sources of lactate ions include

sodium L-lactate, sodium D-lactate, sodium D, L-lactate and zinc L-lactate, although it is believed that any soluble lactate can be used as a source of lactate ions.

The lactate ions function as a pH buffering substance and as an anti-oxidant. Lactate ions are also believed to have an important role in creating an environment that stimulates or supports angiogenesis, the growth and regeneration of new blood vessels, as well as optimising the redox environment for cellular interaction. There may also be other beneficial effects of lactate in the wound environment, but these are not yet fully understood.

The lactate ions are suitably present in an amount of about 0.1% w/v.

The dressing desirably also includes a source of zinc ions. The source of zinc ions may be any compound capable of releasing zinc ions or zinc-containing ions in water. Suitable sources of zinc ions include, for example, zinc lactate, zinc chloride, zinc fluoride, and zinc sulphate.

The function of the zinc ions is as an anti-oxidant and as a general healing and skin benefit agent, with well-known soothing and anti-inflammatory effects. Zinc is an essential nutritional trace element which has numerous functions in the growth and repair of healthy tissues. In addition, zinc ions are known to form stabilising complexes with hydrogen peroxide, thus aiding delivery of hydrogen peroxide to the target site in embodiments discussed below involving hydrogen peroxide.

The zinc ions are suitably present in an amount of about 0.1% w/v.

A currently preferred source of zinc ions and lactate ions is zinc lactate, particularly zinc L-lactate.

The glucose functions to support the biosynthesis of glucose-containing tissue matrix polymers, such as hyaluronic acid, and as an energy source for metabolically active cells, with beneficial effects on wound healing.

The glucose is suitably present in an amount of at least 2.5%, preferably at least 5% by weight of the weight of the hydrated hydrogel material, with higher amounts also being possible. Good results have been obtained with a dressing including 5% by weight of glucose.

The dressing optionally includes a source of iodide ions, e.g. potassium iodide or sodium iodide. Iodide ions can be oxidised to elemental iodine in the presence of a suitable oxidising agent. Iodine is a known powerful antimicrobial agent with beneficial effects on skin, e.g. as disclosed in WO 01/28600 and WO 03/090800.

The iodide ions are suitably present in an amount in the range 0.05% to 0.2% w/v.

The skin dressing of the invention may be used on its own, being located on the skin of a human or animal, e.g. over a wound or on a region of skin to be treated for cosmetic or therapeutic purposes, e.g. for treatment of acne or other skin conditions. The lactate ions, glucose and optional zinc ions are observed to have beneficial effects on skin and wound healing.

Alternatively, the skin dressing or the invention may be used in combination with a source of oxygen or an oxidising agent, such as hydrogen peroxide. For example, the dressing may be used in combination with superposed material that generates hydrogen peroxide, such as layer comprising oxidoreductase enzyme. The oxidoreductase enzyme may be in dry condition, e.g. as disclosed in PCT/GB2004/002374, but is preferably in hydrated condition, e.g. as disclosed in WO 03/090800 and European Patent Application No. 04250508.1 filed 30th January 2004, preferably being included in a hydrated hydrogel, e.g. of materials as discussed above. The oxidoreductase enzyme catalyses reaction of an appropriate substrate with oxygen to produce hydrogen peroxide. Suitable oxidoreductase

enzymes are listed in WO 03/090800. The currently preferred oxidoreductase enzyme is glucose oxidase, with the corresponding substrate being glucose. Thus, the glucose in the dressing of the invention acts as a substrate in this case for generation of hydrogen peroxide.

In another embodiment, the superposed layer may contain a supply of pre-formed hydrogen peroxide, or a hydrogen peroxide precursor substance.

Hydrogen peroxide is a known antimicrobial substance, with many beneficial properties. Where the dressing of the invention includes iodide ions, hydrogen peroxide reacts with iodide ions to generate molecular iodine, which also has beneficial effects on skin. In addition, the rapid decomposition of hydrogen peroxide in contact with tissues and tissue-fluids results in the release of oxygen which is available to help in the healing process and acts against anaerobic bacteria that may be present.

In a preferred aspect, the invention thus provides a skin dressing comprising a first hydrated hydrogel material including a source of lactate ions and a supply of glucose with optional sources of zinc ions and iodide ions; as discussed above, and a second hydrated hydrogel material comprising an oxidoreductase enzyme. The two hydrated hydrogel materials are preferably in the form of layers, sheets or films. The two hydrated hydrogels preferably comprise poly AMPS or salts thereof, desirably in an amount of about 30% by weight of the total weight of the hydrated hydrogels.

In this case the skin dressing is used by being located on the skin of a human or animal, as discussed above, with a superimposed hydrated hydrogel material comprising an oxidoreductase enzyme being located thereon. As well as the beneficial skin effects arising from the lower skin-contacting layer, beneficial effects also arise from generation of hydrogen peroxide and possibly also iodine.

The skin dressing of the invention may also be formulated or constructed in such a way as to control or regulate the rate of diffusion (and hence the effective dose) of hydrogen

peroxide, eg by means of limited available water, by an abundance of hydrogen bonding groups in the gel structure, or by limiting the cross-sectional area of the wound-facing surface of the gel by the incorporation of a scrim that acts as a partial barrier.

The dressing conveniently includes, or is used with, a covering or outer layer for adhering the dressing to the skin of a human or animal subject in known manner.

The skin dressing (or components thereof) is desirably supplied in sterile, sealed, water-impervious packages, e.g. laminated aluminium foil packages.

Example 1

The following composition is a skin treatment product of the form shown in Figure 6 of WO 03/090800, which comprises a glucose-containing hydrogel slab in accordance with the invention as a lower layer of the product, and an optional additional upper layer comprising a poly-AMPS hydrogel that incorporates glucose oxidase.

The hydrogel lower layer in accordance with the invention was formulated to include the following ingredients by weight:

Water (ex Fisher, distilled, de-ionised, analytical grade)	64.7%
Sodium AMPS (ex Lubrizol AMPS 2405 Monomer)	30.0%
Polyethylene glycol diacrylate (PEG400 diacrylate, ex UCB Chemicals available as Ebecryl 11)	0.19%
1-hydroxycyclohexyl phenyl ketone (a photoinitiator, ex Aldrich)	0.01%
Anhydrous glucose (enzyme substrate, ex Fisher)	5.00%
Potassium iodide (ex Fisher)	0.05%
Zinc L-lactate hydrate (ex Aldrich)	0.10%

The mixture was dispensed into casting trays containing either polyester scrim (polyester non-woven, open mesh support, available from HDK Industries Inc, Product Code 5722)

or polyethylene net support, of dimensions 100mm x 100mm, to a depth of about 1.5mm. The polyethylene net support was fabricated from polyester staple fibres thermally bonded by a polyester resin - Product code 5722, from Castle Industries, Greenville, SC 9609, USA. The hydrogel was then set, by irradiation under a UV lamp, for up to 60 seconds and a power rating of approximately 100mW/cm². The hydrogel was then allowed to cool to 30°C or below.

The enzyme-containing hydrogel was formulated to include the following ingredients by weight:

Water (ex Fisher, distilled, de-ionised, analytical grade)	68.6%
Sodium AMPS (ex Lubrizol AMPS 2405 Monomer)	15.0%
Ammonium AMPS (ex Lubrizol AMPS 2411 Monomer)	15.0%
Polyethylene glycol diacrylate (PEG400 diacrylate, ex UCB Chemicals available as Ebecryl 11)	0.19%
1-hydroxycyclohexyl phenyl ketone (a photoinitiator, ex Aldrich)	0.01%
Glucose oxidase (GOX, Biocatalysts, Pontypridd, Code G575P)	0.035%
Zinc L-lactate hydrate (ex Aldrich)	1.0%
Pluronic P65 (block co-polymer of ethylene oxide and propylene oxide, HO-[CH ₂ CH ₂ O] _x -[CH ₂ CHCH ₃ O] _y -[CH ₂ CH ₂ O] _y -H, average MW 3400 (BASF))	0.15%

The mixture was dispensed into casting trays containing polyester scrim (polyester non-woven, open mesh support, available from HDK Industries Inc, Product Code 5722) of dimensions 100mm x 100mm, to a depth of about 1.0mm. The hydrogel was then set, by irradiation under a UV lamp, for up to 30 seconds (typically 25 seconds), and a power rating of approximately 100mW/cm². The hydrogel was then allowed to cool to 30°C or below.

The resulting gel layers were packaged separately in pouches or enclosures impermeable to water or water-vapour, e.g. made of laminated aluminium foil pouches as supplied by Sigma (code Z183407).

In use, eg on a wound, the wound contact layer can be used on its own to provide beneficial effects on a wound environment. Alternatively, the enzyme-containing hydrogel and the glucose-containing hydrogel can be brought together on a wound surface, one overlying the other.

An oxygen-permeable and moisture-permeable covering or overlay such as of polyurethane may be located over the enzyme-containing hydrogel and may be adhered to the skin by means of e.g. acrylic adhesive provided on the lower face of the overlay.

CLAIMS

1. A skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose.
2. A skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose, excluding a hydrated hydrogel comprising the following reagents by weight: 20% sodium AMPS (2-acrylamido-2-methylpropanesulfonic acid, sodium salt (Lubrizol, code 2405), 0.2% poly ethylene glycol 400 diacrylate (UCB Chemicals), 0.01% photoinitiator (1-hydroxycyclohexyl phenyl ketone (Aldrich)), 20% glucose (Fisher), 0.1% zinc lactate (Sigma), 0.05% potassium iodide (Fisher) and to 100% with DI-water.
3. A skin dressing comprising a hydrated hydrogel material comprising a source of lactate ions and a supply of glucose, wherein the glucose is present in an amount of less than 20% by weight of the weight of the hydrated hydrogel material.
4. A skin dressing according to claim 1, 2 or 3, wherein the hydrated hydrogel material is in the form of a layer, sheet or film of material.
5. A skin dressing according to claim 1, 2 or 3, wherein the hydrated hydrogel material is in amorphous form.
6. A skin dressing according to any one of the preceding claims, wherein the hydrated hydrogel comprises hydrophilic polymer material.
7. A skin dressing according to claim 6, wherein the hydrophilic polymer material is selected from polyacrylates and methacrylates.

8. A skin dressing according to claim 7, wherein the hydrophilic polymer material comprises poly 2-acrylamido-2-methylpropane sulphonic acid (poly AMPS) or salts thereof.
9. A skin dressing according to claim 6, 7 or 8, wherein the hydrophilic polymer material is present at a concentration of at least 1%, preferably at least 2%, more preferably at least 5%, yet more preferably at least 10%, or at least 20%, desirably at least 25% and even more desirably at least 30% by weight based on the total weight of the gel.
10. A skin dressing according to any one of the preceding claims, wherein the source of lactate ions is selected from sodium L-lactate, sodium D-lactate, sodium D, L-lactate and zinc L-lactate.
11. A skin dressing according to any one of the preceding claims, further comprising a source of zinc ions.
12. A skin dressing according to claim 11, wherein the source of zinc ions is selected from zinc chloride, zinc fluoride, zinc sulphate and zinc lactate, particularly zinc L-lactate.
13. A skin dressing according to any one of the preceding claims, wherein the glucose is present in an amount of at least 2.5%, preferably at least 5%, by weight of the weight of the hydrated hydrogel material.
14. A skin dressing according to any one of the preceding claims, further comprising a source of iodide ions, e.g. potassium iodide or sodium iodide.
15. A skin dressing according to any one of the preceding claims, in combination with a source of oxygen or an oxidising agent.
16. A skin dressing according to claim 15, in combination with material comprising oxidoreductase enzyme, preferably glucose oxidase.

17. A skin dressing according to claim 16, wherein the layer of material comprising oxidoreductase enzyme comprises a hydrated hydrogel.
18. A skin dressing comprising a first hydrated hydrogel material comprising a source of lactate ions and a supply of glucose with optional sources of zinc ions and iodide ions; and a second hydrated hydrogel material comprising an oxidoreductase enzyme.

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000312

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L15/38 A61L15/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F C08F A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2004/108176 A (INSENSE LIMITED; DAVIS, PAUL, JAMES; AUSTIN, ANDREW, JOHN) 16 December 2004 (2004-12-16) page 5, paragraph 2 page 10 - page 11 page 13 page 14, paragraph 3 claims page 20, paragraph 1	1,3-18
X	US 2003/082225 A1 (MASON PAUL ARTHUR) 1 May 2003 (2003-05-01) paragraphs '0010!, '0012!, '0014!, '0022!, '0029!, '0120!, '0123!, '0126!, '0128!, '0130! claims ----- -/--	1,2,4-7, 10-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

19 May 2005

Date of mailing of the international search report

30/05/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Böhm, I

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000312

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 391 799 A (MASON, JR. ET AL) 5 July 1983 (1983-07-05) column 2, lines 45-50 column 3, lines 10-12,28	1,2
X,P	WO 2004/093786 A (CORIUM INTERNATIONAL; A. V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHE) 4 November 2004 (2004-11-04) paragraphs '0155!, '0156!	1,2,4-7, 10-15
A	WO 97/02811 A (CYGNUS THERAPEUTIC SYSTEMS) 30 January 1997 (1997-01-30) page 2, line 15 - page 3, line 19 page 6, lines 25-34 page 7, lines 9-27 page 10, lines 9-21 page 11, lines 3-20 page 14, lines 9-15 page 16, lines 22-35 examples claims 1,8,9	1-9,13
A	WO 03/090800 A (INSENSE LTD ; AUSTIN ANDREW JOHN (GB); DAVIS PAUL JAMES (GB)) 6 November 2003 (2003-11-06) cited in the application page 6, paragraph 2 page 33, paragraph 4 claims	1,3,6-9, 13,15-17
A	WO 01/28600 A (OXIBIO INC) 26 April 2001 (2001-04-26) cited in the application page 6, lines 1-12 claims 4,5,7,9	1-3, 15-17
A	US 4 576 817 A (MONTGOMERY ROBERT E ET AL) 18 March 1986 (1986-03-18) column 3 claims; example 1	1-3, 15-17
A	DE 40 26 153 A (SEBAPHARMA GMBH & CO) 20 February 1992 (1992-02-20) column 1, lines 59-68 column 3, lines 8-14	1,2,4,6
A	WO 01/96422 A (DONNELLY MICHAEL JOSEPH ; MUNRO HUGH SEMPLE (GB); PAGE ALISON (GB); FI) 20 December 2001 (2001-12-20) cited in the application page 5, lines 8-16 claims; example 1; table 2	1,2,6-8

-/--

INTERNATIONAL SEARCH REPORT

PCI/GB2005/000312

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2003/225356 A1 (KULICHIKHIN VALERY G ET AL) 4 December 2003 (2003-12-04) the whole document	1,2
A,P	----- WO 2004/112851 A (JOHNSON & JOHNSON MEDICAL LIMITED; FOSTER, SIMON) 29 December 2004 (2004-12-29) page 1 - page 2 page 3 page 10 - page 12 page 13, lines 30-33 page 17, lines 12-33 page 18, lines 6-12 claims -----	1,4-9, 15-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2005/000312

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004108176	A	16-12-2004	WO 2004108176 A1	16-12-2004
			WO 2004108917 A1	16-12-2004
US 2003082225	A1	01-05-2003	CA 2463309 A1	01-05-2003
			EP 1441635 A2	04-08-2004
			WO 03034900 A2	01-05-2003
US 4391799	A	05-07-1983	NONE	
WO 2004093786	A	04-11-2004	US 2004242770 A1	02-12-2004
			WO 2004093786 A2	04-11-2004
WO 9702811	A	30-01-1997	AT 250928 T	15-10-2003
			AU 706662 B2	17-06-1999
			AU 6492896 A	10-02-1997
			CA 2226176 A1	30-01-1997
			DE 69630226 D1	06-11-2003
			DE 69630226 T2	05-08-2004
			DK 840597 T3	26-01-2004
			EP 0840597 A1	13-05-1998
			ES 2208754 T3	16-06-2004
			JP 10509052 T	08-09-1998
			JP 3201482 B2	20-08-2001
			PT 840597 T	27-02-2004
			WO 9702811 A1	30-01-1997
			US 2004062759 A1	01-04-2004
WO 03090800	A	06-11-2003	EP 1358893 A1	05-11-2003
			AU 2003222985 A1	10-11-2003
			CA 2483214 A1	06-11-2003
			EP 1496951 A1	19-01-2005
			WO 03090800 A1	06-11-2003
WO 0128600	A	26-04-2001	AU 1102801 A	30-04-2001
			EP 1221985 A1	17-07-2002
			JP 2003512095 T	02-04-2003
			WO 0128600 A1	26-04-2001
			US 6592890 B1	15-07-2003
US 4576817	A	18-03-1986	EP 0236610 A1	16-09-1987
DE 4026153	A	20-02-1992	DE 4026153 A1	20-02-1992
			AT 114482 T	15-12-1994
			DE 59103721 D1	12-01-1995
			DK 543868 T3	15-05-1995
			WO 9203172 A1	05-03-1992
			EP 0543868 A1	02-06-1993
			ES 2064118 T3	16-01-1995
			JP 6500028 T	06-01-1994
WO 0196422	A	20-12-2001	AU 6413101 A	24-12-2001
			CA 2412811 A1	20-12-2001
			EP 1292628 A1	19-03-2003
			WO 0196422 A1	20-12-2001
			JP 2004503624 T	05-02-2004
			US 2003147835 A1	07-08-2003
US 2003225356	A1	04-12-2003	AU 2003231840 A1	12-12-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2005/000312

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003225356 A1		EP 1513561 A2	16-03-2005
		WO 03099344 A2	04-12-2003
WO 2004112851 A	29-12-2004	GB 2403146 A	29-12-2004
		WO 2004112851 A1	29-12-2004